

The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma

Milan (Italy), 11 November 2009 - MolMed S.p.A. (Milan:MLM) announces that the European Commission has granted Orphan Drug designation for MolMed's investigational new antitumour therapeutic drug NGR-hTNF in the treatment of hepatocellular carcinoma (HCC), i.e. primary liver cancer. The Commission decision of 9 November 2009 follows the positive opinion released by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), reporting that "*NGR-hTNF may be of significant benefit to those affected by HCC, based on a potential clinically relevant advantage based on the activity of the product, and its potential use in combination therapy as shown in preclinical models*". NGR-hTNF is now listed in the Community Register of orphan medicinal products for human use with the code EU/3/09/686. NGR-hTNF has recently received Orphan Drug designation for the same indication from the US Food and Drug Administration (FDA).

"Orphan Drug designation for NGR-hTNF in primary liver cancer in both the EU and the US is an important acknowledgement of our efforts in the development of NGR-hTNF in the treatment of this very poor-prognosis disease, currently tested in a Phase II trial", comments Claudio Bordignon, MolMed's chairman and CEO.

Updated results of the Phase II trial of NGR-hTNF as single agent for liver cancer (NGR008), involving 40 patients, were presented at the ECCO-ESMO Congress in September 2009. Top-line study results include a median survival time of 8.9 months. The 1-year and 2-year survival rates were 27% and 17%, respectively. Disease control was achieved in 30% of patients, with a median duration of 4.3 months. A complete tumour eradication is still ongoing since May 2008, and an additional partial tumour regression lasting for 4.4 months was observed.

About Orphan Drug designation in the EU

European Orphan Drug designation is granted to therapeutics intended for treatment of life-threatening or chronically debilitating pathologies affecting no more than 5 in 10,000 people. The orphan medicinal products designated to date cover a wide variety of rare diseases, for which there are either no or few satisfactory treatment options. The Orphan Drug designation confers several benefits to drug development, including the possibility to reduce time to reach the market, protocol assistance and scientific advice provided by the EMA throughout the drug development process, reduced fees for filing drug approval and, upon authorisation, marketing exclusivity for a period of 10 years.

About hepatocellular carcinoma

Hepatocellular carcinoma is a primary cancer of the liver. Most cases are secondary to either a viral infection (hepatitis B or C) or cirrhosis. In countries where hepatitis is not endemic, most malignant cancers in the liver are not primary tumours but metastases (spread) of cancer from a different primary tumour site, e.g. the colon. Treatment options of liver cancer and prognosis are dependent on many factors, but especially on tumour stage. Tumour grade is also important: high-grade tumors will have a poor prognosis, while low-grade tumors may go unnoticed for many years. The usual outcome is poor, because only 10-20% of hepatocellular carcinomas can be removed completely using surgery. If the cancer cannot be completely removed, the untreated disease in advanced stage is usually associated to a median survival time of about 6 months.

About NGR-hTNF

NGR-hTNF is a vascular targeting agent with unique mode of action, and a first-in-class compound in the class of peptide/cytokine complexes able to selectively target the tumour vasculature. It consists of a tumour homing peptide (NGR) that selectively binds tumour blood vessels, fused to the powerful

human anticancer cytokine TNF. NGR-hTNF is undergoing clinical development both as single agent and in combination with several different chemotherapeutic agents. Indications investigated in Phase II trials as single agent include, besides liver cancer, colorectal cancer and malignant pleural mesothelioma. Phase II trials in combination therapy include: with Xelox for colorectal cancer; with doxorubicin for small-cell lung cancer, and for ovarian cancer; with cisplatin-based regimens (cis/gem or cis/pem) in a randomised trial for non-small cell lung cancer, *versus* chemotherapy alone. MolMed is also conducting a Phase I trial aimed at the exploration of safety and preliminary anticancer activity of NGR-hTNF at high doses. In 2008, NGR-hTNF was granted Orphan Drug designation for malignant mesothelioma both in the EU and in the US.

About MolMed

MolMed S.p.A is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. In addition to NGR-hTNF, MolMed's pipeline includes another anticancer therapeutic in clinical development, TK, a cell-based therapy enabling bone marrow transplant from partially compatible donors, in Phase III for high-risk acute leukaemias. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The company's shares (MLM) are listed at the Standard segment (class I) of the MTA managed by Borsa Italiana.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999 as subsequently amended.

DISCLAIMER

This press release may contain certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.

For further information, please contact:

Holger Neecke
Director Business Development, Investor Relations
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Elena Lungagnani
Communication Manager
MolMed S.p.A.
phone: +39 02 21277.207
fax: +39 02 21277.325
e-mail: media.relations@molmed.com